Publish in this journal
Journal Information
Vol. 64. Issue 11.
Pages 962-964 (November 2011)
Vol. 64. Issue 11.
Pages 962-964 (November 2011)
Full text access
Control of Coronary Heart Disease Risk Factors and Evidence-Based Therapies: Joint Efforts for Coronary Heart Disease Prevention in Spain
Control de los factores de riesgo coronarios y terapias basadas en la evidencia: esfuerzos coordinados para la prevención cardiovascular en España
Visits
13833
Manuel Francoa,
,b
, Richard Cooperc, Usama Bilala, Valentín Fustera,d
a Departamento de Epidemiología, Aterotrombosis e Imagen, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
b Department of Epidemiology, Welch Center for Prevention, Epidemiology and Cardiovascular Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
c Department of Preventive Medicine and Epidemiology, Loyola University Medical School, Maywood, Illinois, United States
d Zena and Michael A. Wiener Cardiovascular Institute, and the Marie-Josee and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai School of Medicine, New York, United States
Related content
Gemma Flores-Mateo, María Grau, Martin O’Flaherty, Rafel Ramos, Roberto Elosua, Concepción Violan-Fors, Miquel Quesada, Ruth Martí, Joan Sala, Jaume Marrugat, Simon Capewell
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Cardiovascular disease (CVD) is the leading cause of death in high-income countries such as Spain, as well as low- and middle-income countries.1 In Spain, CVD has continued to rank as the number one cause of death for the last several decades. Large differences between countries in terms of CVD mortality have been described.2 Spain, along with France, Japan, and Italy, are considered low-risk CVD countries.3 Two disease categories account for the vast majority of cardiovascular disease events: namely coronary heart disease (CHD) and stroke.

In this issue of Revista Española de Cardiología, Flores-Mateo et al.4 shed new light on the factors underlying the reduction of CHD mortality in a low-risk country such as Spain during the period of 1988-2005. By using the IMPACT model5 they have quantified the contribution of relevant CHD risk factors and evidence-based therapies to the overall decline of CHD mortality. This model has been applied and validated in other countries, such as the United States, Finland, the United Kingdom, and Italy. The IMPACT model aggregates risk factors (total cholesterol, systolic blood pressure, smoking, diabetes, body mass index, and physical inactivity) and evidence-based therapies (management of acute coronary syndromes, secondary prevention therapies, chronic angina, and heart failure treatments and the control of hypertension and hyperlipidemia) to disentangle the contribution of each factor to the variation in CHD mortality.

According to the study by Flores-Mateo et al.,4 52% of the decline in CHD mortality can be explained by population-wide risk factor changes over time whereas CHD evidence-based therapies for patients with established disease have contributed the remaining 48% (Figure 1). The largest contributor to the mortality decline in Spain was the improvement in total cholesterol levels that is estimated to have prevented or postponed 23.9% of deaths, while improvements in systolic blood pressure may have accounted for 14.9% of CHD mortality decline. These results also highlight the fact that not all risk factors have followed the beneficial trends for CHD. The increases observed in body mass index in men, smoking in women, and diabetes in both sexes have hindered the CHD mortality decline in Spain. Among evidence-based therapies, the management of acute coronary syndromes (acute myocardial infarction and unstable angina) prevented or postponed 11% of CHD deaths whereas secondary prevention (after infarction or revascularization) was responsible for 10% of such decline.

Figure 1. Coronary heart disease mortality decline in Spanish men (A) and women (B) from 1988 to 2005 as explained by risk factor changes and evidence-based therapies. DM, diabetes mellitus; BMI, body mass index; CHD, coronary heart disease; SBP, systolic blood pressure.

The results of the Flores-Mateo et al. study4 are consistent with the application of the IMPACT model in other populations and with a recently published analysis of a British cohort attributing 48% of the decline in CHD mortality to changes in CHD risk factors.6

Both population-wide improvements in CHD risk factors and improved delivery of evidence-based therapies (by increasing the percentage of patients receiving them and by improving adherence) are key points to progress in CHD prevention.7

Several relevant points for the prevention of CHD in Spain are raised in this elegant application of the IMPACT methodology:

  • • CHD risk factors such as body weight, diabetes mellitus, and smoking continue to impede the decline of CHD mortality in Spain.

  • • Relevant sex differences in terms of risk factor distribution should be acknowledged.

  • • There is great room for improvement of CHD evidence-based therapies uptake and adherence.

  • • Health policies directly related with cardiovascular prevention may offer great opportunities in Spain.

  • • Spain, along with other high-income countries, is in need of a state-of-the-art CVD surveillance network.

As Flores-Mateo et al.4 report, increasing body weight, diabetes, and smoking contributed to rising CHD deaths in Spain. (Doted lines in Figure 1) This phenomenon has been previously well described in the United States.8 Special strategies should be implemented to tackle smoking, diabetes, and obesity, which represent our main opportunity for CHD prevention in the coming decades.

It is interesting to note the sex differences in the distribution of CHD risk factors (Panels A and B in Figure 1). Smoking rates have steadily decreased in men (from 52.5% in 1988 to 32.5% in 2005) while they have increased in women (from 9% in 1988 to 19.7% in 2005) during the last decades in Spain. In a similar British study,6 smoking trends decreased in both sexes. Prevention programs should acknowledge relevant sex differences. There are also important sex differences regarding evidence-based therapies. The current analysis does not address possible differences between sexes in therapy uptake, which may be relevant, especially when it comes to the management of acute coronary syndromes.9

Evidence-based therapies are also a cornerstone of CHD mortality prevention,10 as this study and the previous IMPACT applications have consistently shown.7

The design and evaluation of programs aimed at improving therapies uptake and adherence should be one of our main foci. Previous attempts have shown increasing success in the control of CHD risk factors such as hypertension by using multifactorial interventions to increase adherence to treatment within the primary care system.11

Previous health policy driven population-wide interventions have proven effective at reducing CHD mortality.12 Public health has always been a hybrid discipline, using the tools of biological science and statistics to build the required knowledge base and then applying this knowledge in the world of politics and social relations. The knowledge required for cardiovascular disease prevention is now available; however, policy interventions have fallen short. Prevention of CHD in Spain will require a set of health policies to ensure the adoption of healthy lifestyles. The basic elements of such policies are outlined in Table 1, differentiating 3 levels of action – the policymaking, health systems, and individual levels, helping individuals to sustain the necessary behavior changes.10 A contemporary example of a public health intervention directed to children that integrates all aspects of individual behavior changes in Spain is the SI! (Salud Integral) program, sponsored by the SHE foundation,13 which undertakes the task of promoting cardiovascular health among school children.

Table 1. Public Health Interventions by Specific Cardiovascular Disease Risk Factors at Three Levels: Policy, Health System, and Behavioral Change.

CVD risk factors Policy level interventions Health systems strengthening and integration Behavior change interventions
Smoking Tobacco controlPrograms for children and adolescents Primary care programs for smoking cessation Avoiding smoking uptake by young individualsSmoking cessation
Physical inactivity Built environment policiesRecreational facilitiesPromoting walking and bicycling as means of transportation Primary care programs for increasing physical activity Promotion of physical activityLeisure vs utilitarian physical activity
Unhealthy dietary patterns Food environment:Making fruits and vegetables more available and less expensiveReducing the availability and increasing the prices of high-energy foodsImproving school cafeterias Primary care programs and units for improving dietary quality Nutritional health education programs in television programs and schools
Biological risk factors(Obesity, Cholesterol, Diabetes, Hypertension) Campaigns for risk factors awareness and control * National salt reduction * Creating primary care units with multidisciplinary teams to prevent and control body weight, lipids levels, glucose levels, and BP Nutritional educationPhysical activity programsDevelopment of home BP monitoring programs

BP, blood pressure; CVD, cardiovascular disease.

* See the above interventions for physical activity and diet.

In order to develop such policies, prevention efforts must be informed by a well developed monitoring system that would let us determine the distribution of relevant CHD risk factors, allowing preventive measures to be both adequate and comprehensive.10 Models such as IMPACT need to be informed by a network that gathers data in a valid and representative way and is able to picture the surveyed region taking into account social, economic, and health differences. Current monitoring systems have helped us determine and explain the causes of previous decreases in CHD mortality.14, 15

In summary, the informative results of applying the IMPACT model to the Spanish population help to confirm the ongoing importance of population-wide risk factor improvements and the appropriate delivery of evidence-based therapies, highlighting the considerable differences in the distribution of risk factors between men and women and the need for strategies to control smoking, obesity, and diabetes, factors which are impeding the overall downward CHD mortality trend in Spain.

CONFLICT OF INTEREST

None declared.

Corresponding author: Departamento de Epidemiología, Aterotrombosis e Imagen, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, 28029 Madrid, Spain. mfranco@cnic.es

Bibliography
[2]
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al..
Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee..
Circulation. , 119 (2009), pp. 480-486
[3]
Grau M, Subirana I, Elosua R, Solanas P, Ramos R, Masiá R, et al..
Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain..
Eur J Cardiovasc Prev Rehabil. , 14 (2007), pp. 653-659
[4]
Flores-Mateo G, Grau G, O’Flaherty M, Ramos R, Elosua R, Violan-Fors C, et al..
Análisis de la disminución de la mortalidad por enfermedad coronaria en una población mediterránea: España 1988-2005..
Rev Esp Cardiol. , 64 (2011), pp. 988-996
[5]
Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al..
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000..
N Engl J Med. , 356 (2007), pp. 2388-2398
[6]
Hardoon SL, Morris RW, Whincup PH, Shipley MJ, Britton AR, Masset G, et al. Rising adiposity curbing decline in the incidence of myocardial infarction: 20-year follow-up of British men and women in the Whitehall II cohort. Eur Heart J. 2011 June 8.[Epub ahead of print]..
[7]
Ford ES, Capewell S..
Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care..
Annu Rev Public Health. , 32 (2011), pp. 5-22
[8]
Capewell S, Hayes DK, Ford ES, Critchley JA, Croft JB, Greenlund KJ, et al..
Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000..
Am J Epidemiol. , 170 (2009), pp. 229-236
[9]
Marrugat J, Sala J, Masiá R, Pavesi M, Sanz G, Valle V, et al..
Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera..
JAMA. , 280 (1998), pp. 1405-1409
[10]
Franco M, Cooper RS, Bilal U, Fuster V..
Challenges and opportunities for cardiovascular disease prevention..
Am J Med. , 124 (2011), pp. 95-102
[11]
Pladevall M, Brotons C, Gabriel R, Arnau A, Suarez C, De la Figuera M, et al..
Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study)..
Circulation. , 122 (2010), pp. 1183-1191
[12]
Capewell S, O’Flaherty M..
Rapid mortality falls after risk-factor changes in populations..
[13]
Taylor J..
Science is the fundamental building block for every project in The Foundation for Science, Health, and Education (SHE)..
Eur Heart J. , 32 (2011), pp. 662-663
[14]
Franco M, Orduñez P, Caballero B, Tapia Granados JA, Lazo M, Bernal JL, et al..
Impact of energy intake, physical activity, and population-wide weight loss on cardiovascular disease and diabetes mortality in Cuba, 1980-2005..
Am J Epidemiol. , 166 (2007), pp. 1374-1380
[15]
Franco M, Orduñez P, Caballero B, Cooper RS..
Obesity reduction and its possible consequences: what can we learn from Cuba's Special Period?..
CMAJ. , 178 (2008), pp. 1032-1034
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?